Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 6/20 | 0.81 |
| ▸ | MEN1 | O00255 | 9/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.74 |
| ▸ | CYP1A2 | P05177 | 8/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.74 |
| ▸ | CYP1A1 | P04798 | 7/20 | 0.74 |
| ▸ | CYP1B1 | Q16678 | 7/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.74 |
| ▸ | RECQL | P46063 | 6/20 | 0.74 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.74 |
| ▸ | MAPT | P10636 | 6/20 | 0.74 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.74 |
| ▸ | FTO | Q9C0B1 | 5/20 | 0.74 |
| ▸ | XDH | P47989 | 5/20 | 0.74 |
| ▸ | MAOA | P21397 | 5/20 | 0.74 |
| ▸ | IPMK | Q8NFU5 | 5/20 | 0.74 |
| ▸ | IP6K2 | Q9UHH9 | 5/20 | 0.74 |
| ▸ | POLB | P06746 | 5/20 | 0.74 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.74 |
| ▸ | APEX1 | P27695 | 4/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30255771 | 0.90 | ABCB1 (1.00) | ABCB1MEN1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL4034698 | 0.90 | ABCB1 (1.00) | ABCB1MEN1KMT2ACYP1A2CYP3A4 | |
| Laricytrin SCHEMBL19213534 | 0.88 | ABCB1 (0.83) | ABCB1MEN1KMT2ACYP1A2CYP3A4 | |
| Laricytrin SCHEMBL29929477 | 0.88 | ABCB1 (0.83) | ABCB1MEN1KMT2ACYP1A2CYP3A4 | |
| Syringetin SCHEMBL810981 | 0.86 | ABCB1 (0.85) | ABCB1MEN1KMT2ACYP1A2CYP3A4 | |
| Syringetin SCHEMBL29929167 | 0.86 | ABCB1 (0.85) | ABCB1MEN1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL10041306 | 0.86 | POLB (0.77) | ABCB1MEN1KMT2ACYP1A2CYP3A4 | |
| Myricetin SCHEMBL19302 | 0.86 | MEN1 (1.00) | ABCB1MEN1KMT2ACYP1A2CYP3A4 | |
| Myricetin SCHEMBL3503992 | 0.86 | MEN1 (1.00) | ABCB1MEN1KMT2ACYP1A2CYP3A4 | |
| Myricetin SCHEMBL29357150 | 0.86 | MEN1 (1.00) | ABCB1MEN1KMT2ACYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240315965-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2024-09-26 | — | — | US | claimed |
| WO-2023064318-A1 | BIPHASIC COMPOSITIONS COMPRISING ONE OR BOTH OF CARBONATE AND PHOSPHATE | Natural Extraction Systems, LLC (US) | 2023-04-20 | — | — | WO | claimed |
| CN-115251089-B | Application of fleabane extract and method for promoting growth of crops | 中国科学院昆明植物研究所 | 2023-03-10 | — | — | CN | claimed |
| CN-115251089-A | Application of flea grass extract and method for promoting growth of crops | 中国科学院昆明植物研究所 | 2022-11-01 | — | — | CN | claimed |
| WO-2022182527-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2022-09-01 | — | — | WO | claimed |
| US-11786503-B2 | Pharmaceutical compositions and methods for countering chemotherapy induced cardiotoxicity | AURANSA INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-11786503-B2 | Pharmaceutical compositions and methods for countering chemotherapy induced cardiotoxicity | AURANSA INC. (US) | 2023-10-17 | — | — | US | disclosed |
| WO-2023064318-A1 | BIPHASIC COMPOSITIONS COMPRISING ONE OR BOTH OF CARBONATE AND PHOSPHATE | Natural Extraction Systems, LLC (US) | 2023-04-20 | — | — | WO | disclosed |
| CN-115251089-B | Application of fleabane extract and method for promoting growth of crops | 中国科学院昆明植物研究所 | 2023-03-10 | — | — | CN | disclosed |
| CN-115251089-A | Application of flea grass extract and method for promoting growth of crops | 中国科学院昆明植物研究所 | 2022-11-01 | — | — | CN | disclosed |
| US-20220133684-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR COUNTERING CHEMOTHERAPY INDUCED CARDIOTOXICITY | AURANSA INC. (US) | 2022-05-05 | — | — | US | disclosed |
| US-11166936-B2 | Pharmaceutical compositions and methods for countering chemotherapy induced cardiotoxicity | AURANSA INC. (US) | 2021-11-09 | — | — | US | disclosed |
| US-20180222878-A1 | COMPOSITION FOR INHIBITING FORMATION OF SNARE COMPLEX, CONTAINING MYRICETIN DERIVATIVES | Research & Business Foundation Sungkyunkwan University (KR) | 2018-08-09 | — | — | US | disclosed |
| WO-2017136774-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR COUNTERING CHEMOTHERAPY INDUCED CARDIOTOXICITY | STEM CELL THERANOSTICS, INC. (US) | 2017-08-10 | — | — | WO | disclosed |
| US-20170224654-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR COUNTERING CHEMOTHERAPY INDUCED CARDIOTOXICITY | STEM CELL THERANOSTICS, INC. (US) | 2017-08-10 | — | — | US | disclosed |
| US-20170224654-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR COUNTERING CHEMOTHERAPY INDUCED CARDIOTOXICITY | STEM CELL THERANOSTICS, INC. (US) | 2017-08-10 | — | — | US | disclosed |
| US-8367121-B2 | Nutraceutical agent for attenuating the neurodegenerative process associated with Parkinson's disease | FLORIDA A & M UNIVERSITY (US) | 2013-02-05 | — | — | US | disclosed |
| US-20100150895-A1 | Nutraceutical agent for attenuating the Neurodegenerative process associated with Parkinson's disease | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-06-17 | — | — | US | disclosed |
| US-20080292607-A1 | Nutraceutical agent for attenuating the neurodegenerative process associated with Parkinson's disease | MAZZIO ELIZABETH | 2008-11-27 | — | — | US | disclosed |
| US-20070116779-A1 | Comprehensive nutraceutical agent for treatment/ prevention of Parkinson's disease | MAZZIO ELIZABETH | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11166936-B2 | Pharmaceutical compositions and methods for countering chemotherapy induced cardiotoxicity | RDX, TNNT2, CHLSN | ABCB1 106/4885MEN1 1453/4885KMT2A 1476/4885 |
| US-20170224654-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR COUNTERING CHEMOTHERAPY INDUCED CARDIOTOXICITY | RDX, TNNT2, CHLSN | ABCB1 106/4885MEN1 1453/4885KMT2A 1476/4885 |
| US-11786503-B2 | Pharmaceutical compositions and methods for countering chemotherapy induced cardiotoxicity | RDX, TNNT2, CHLSN | ABCB1 106/4885MEN1 1453/4885KMT2A 1476/4885 |
| US-20220133684-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR COUNTERING CHEMOTHERAPY INDUCED CARDIOTOXICITY | RDX, TNNT2, CHLSN | ABCB1 106/4885MEN1 1453/4885KMT2A 1476/4885 |
| US-20180222878-A1 | COMPOSITION FOR INHIBITING FORMATION OF SNARE COMPLEX, CONTAINING MYRICETIN DERIVATIVES | VAMP7, FLOT1, SNAP29 | ABCB1 673/4885MEN1 598/4885KMT2A 2472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.